BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang JF, Shu ZJ, Xie CY, Li Q, Jin XH, Gu W, Jiang FJ, Ling CQ. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PLoS One. 2014;9:e88182. [PMID: 24609114 DOI: 10.1371/journal.pone.0088182] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang TT, Zhao XQ, Liu Z, Mao ZY, Bai L. Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients. Clin Transl Oncol. 2016;18:831-840. [PMID: 26577107 DOI: 10.1007/s12094-015-1446-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
2 Pinato DJ, Karamanakos G, Ishizuka M, Smirne C, Pirisi M, Kubota K, Sharma R. The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application. Liver Int 2015;35:2458-65. [PMID: 25845291 DOI: 10.1111/liv.12841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Yim HJ, Suh SJ, Um SH. Current management of hepatocellular carcinoma: an Eastern perspective. World J Gastroenterol. 2015;21:3826-3842. [PMID: 25852267 DOI: 10.3748/wjg.v21.i13.3826] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
4 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol. 2015;7:406-424. [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
5 Zhang LX, Luo PQ, Chen L, Song DD, Xu AM, Xu P, Xu J. Model to Predict Overall Survival in Patients With Hepatocellular Carcinoma After Curative Hepatectomy. Front Oncol 2020;10:537526. [PMID: 33747893 DOI: 10.3389/fonc.2020.537526] [Reference Citation Analysis]
6 Wang Y, Xiang X, Chen L, Cao Z, Bao R, Zhou H, Tang W, Lu J, Lin L, Xie Q, Bao S, Wang H. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy. Oncotarget 2016;7:58553-62. [PMID: 27329718 DOI: 10.18632/oncotarget.10155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hu S, Zhu Y, Xia X, Xu X, Chen F, Miao X, Chen X. Ginsenoside Rg3 Prolongs Survival of the Orthotopic Hepatocellular Carcinoma Model by Inducing Apoptosis and Inhibiting Angiogenesis. Anal Cell Pathol (Amst) 2019;2019:3815786. [PMID: 31534898 DOI: 10.1155/2019/3815786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, Wan G, Wang X. Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine (Baltimore). 2015;94:e639. [PMID: 25789957 DOI: 10.1097/md.0000000000000639] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
9 Tian H, Cao S, Hu M, Wang Y, Fu Q, Pan Y, Qin T. Identification of predictive factors in hepatocellular carcinoma outcome: A longitudinal study. Oncol Lett 2020;20:765-73. [PMID: 32566003 DOI: 10.3892/ol.2020.11581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Huang Y, Chen H, Zeng Y, Liu Z, Ma H, Liu J. Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection. Front Oncol 2020;10:593741. [PMID: 33598425 DOI: 10.3389/fonc.2020.593741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Du Y, Han X, Ding YB, Yin JH, Cao GW. Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol 2016;22:6565-72. [PMID: 27547000 DOI: 10.3748/wjg.v22.i29.6565] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:1033-50. [PMID: 32107625 DOI: 10.1007/s00432-020-03135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Xie X, Yao M, Chen X, Lu W, Lv Q, Wang K, Zhang L, Lu F. Reduced red blood cell count predicts poor survival after surgery in patients with primary liver cancer. Medicine (Baltimore) 2015;94:e577. [PMID: 25715259 DOI: 10.1097/MD.0000000000000577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
14 Sun P, Chen S, Li Y. The association between pretreatment serum alkaline phosphatase and prognosis in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2020;99:e19438. [PMID: 32176073 DOI: 10.1097/MD.0000000000019438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Adhoute X, Pénaranda G, Raoul JL, Blanc JF, Edeline J, Conroy G, Perrier H, Pol B, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Bronowicki J, Bourlière M. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C. European Journal of Gastroenterology & Hepatology 2016;28:433-40. [DOI: 10.1097/meg.0000000000000558] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
16 Chen ZH, Hong YF, Lin J, Li X, Wu DH, Wen JY, Chen J, Ruan DY, Lin Q, Dong M, Wei L, Wang TT, Lin ZX, Ma XK, Wu XY, Xu R. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett 2017;14:705-14. [PMID: 28693224 DOI: 10.3892/ol.2017.6222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ni XC, Yi Y, Fu YP, He HW, Cai XY, Wang JX, Zhou J, Cheng YF, Jin JJ, Fan J, Qiu SJ. Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma. Medicine (Baltimore) 2015;94:e1486. [PMID: 26356714 DOI: 10.1097/MD.0000000000001486] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
18 Tannus RK, Almeida-Carvalho SR, Loureiro-Matos CA, Miziara-Gonzalez A, Salzedas-Netto AA, Szejnfeld D, D'Ippolito G, Pereira-Lanzoni V, Souza-Silva I. Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. PLoS One 2018;13:e0194922. [PMID: 29617435 DOI: 10.1371/journal.pone.0194922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
19 Gan W, Huang JL, Zhang MX, Fu YP, Yi Y, Jing CY, Fan J, Zhou J, Qiu SJ. New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. J Surg Oncol 2018;117:1540-7. [PMID: 29572833 DOI: 10.1002/jso.25046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
20 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016;8:703-15. [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
21 Yang SZ, Zhang W, Yuan WS, Dong JH. Recurrence of Hepatocellular Carcinoma With Epithelial-Mesenchymal Transition After Spontaneous Regression: A Case Report. Medicine (Baltimore) 2015;94:e1062. [PMID: 26181539 DOI: 10.1097/MD.0000000000001062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Takada H, Amemiya F, Yasumura T, Yoda H, Okuwaki T, Imagawa N, Shimamura N, Tanaka K, Kadokura M, Maekawa S, Enomoto N. Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma. Sci Rep 2020;10:10186. [PMID: 32576956 DOI: 10.1038/s41598-020-67147-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 102] [Article Influence: 21.2] [Reference Citation Analysis]